260 related articles for article (PubMed ID: 22963187)
21. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia.
Faunce TS; Tomossy GF
Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881
[TBL] [Abstract][Full Text] [Related]
22. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
23. Uptake of new medicines in New Zealand: evidence of a waiting list.
Barber JM; Sheehy KP
N Z Med J; 2015 Apr; 128(1412):10-20. PubMed ID: 25899488
[TBL] [Abstract][Full Text] [Related]
24. Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications.
Sarkisova F; Lessing C; Stretton C
J Prim Health Care; 2022 Apr; 14(1):13-20. PubMed ID: 35417327
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Rivera VM
Neurol Ther; 2019 Dec; 8(2):177-184. PubMed ID: 31313222
[TBL] [Abstract][Full Text] [Related]
26. Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand.
Evans J; Laking G; Strother M; Wang T; Metcalfe S; Blick G; Pauls R; Crausaz S
Semin Oncol; 2016 Dec; 43(6):625-637. PubMed ID: 28061980
[TBL] [Abstract][Full Text] [Related]
27. Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States.
Roughead EE; Lopert R; Sansom LN
Value Health; 2007; 10(6):514-20. PubMed ID: 17970935
[TBL] [Abstract][Full Text] [Related]
28. Access to prescribing information for paediatric medicines in the USA: post-modernization.
Young L; Lawes F; Tordoff J; Norris P; Reith D
Br J Clin Pharmacol; 2009 Mar; 67(3):341-6. PubMed ID: 19220278
[TBL] [Abstract][Full Text] [Related]
29. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
30. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
31. Medicines and the media: news reports of medicines recommended for government reimbursement in Australia.
Robertson J; Walkom EJ; Bevan MD; Newby DA
BMC Public Health; 2013 May; 13():489. PubMed ID: 23687910
[TBL] [Abstract][Full Text] [Related]
32. Patient access to new cancer drugs in the United States and Australia.
Wilson A; Cohen J
Value Health; 2011; 14(6):944-52. PubMed ID: 21914517
[TBL] [Abstract][Full Text] [Related]
33. From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand, Taiwan, and Thailand.
Cook G; Kim H
Value Health Reg Issues; 2015 May; 6():40-45. PubMed ID: 29698191
[TBL] [Abstract][Full Text] [Related]
34. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
[TBL] [Abstract][Full Text] [Related]
35. Subsidised access to new melanoma drugs: in need of further innovation?
Wonder M; Fisher R
N Z Med J; 2016 Aug; 129(1440):37-54. PubMed ID: 27538038
[TBL] [Abstract][Full Text] [Related]
36. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
37. Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?
Mason A; Drummond M; Ramsey S; Campbell J; Raisch D
J Clin Oncol; 2010 Jul; 28(20):3234-8. PubMed ID: 20498408
[TBL] [Abstract][Full Text] [Related]
38. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
Tordoff JM; Norris PT; Reith DM
Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
[TBL] [Abstract][Full Text] [Related]
39. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
40. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
Inotai A; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
